Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian surveyAlice Indini, Francesco Grossi, C. Aschele et al.|European Journal of Cancer|2020Cited by 111
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second waveAlice Indini, Livio Blasi, Graziella Pinotti et al.|European Journal of Cancer|2021Cited by 22
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO StudyNicla La Verde, Sandro Barni, Livio Blasi et al.|Clinical Breast Cancer|2020Cited by 17
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Elena Cazzaniga, Valter Torri, Claudio Verusio et al.|Oncotarget|2018Cited by 4